Oaktree Acquisition Corp. III Life Sciences OACC
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.89% | 2.63% | 369.02% | 369.02% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.89% | 2.63% | 369.02% | 369.02% | -- |
| Operating Income | 2.89% | -2.63% | -369.02% | -369.02% | -- |
| Income Before Tax | -14.39% | -15.96% | 4,188.77% | 4,188.77% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.39% | -15.96% | 4,188.77% | 4,188.77% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.39% | -15.96% | 4,188.77% | 4,188.77% | -- |
| EBIT | 2.89% | -2.63% | -369.02% | -369.02% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -14.30% | -16.00% | 827.27% | 827.27% | 2,005.00% |
| Normalized Basic EPS | -14.47% | -16.11% | 824.64% | 824.64% | 2,008.00% |
| EPS Diluted | -14.30% | -16.00% | 827.27% | 827.27% | 2,005.00% |
| Normalized Diluted EPS | -14.47% | -16.11% | 824.64% | 824.64% | 2,008.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 461.89% | 461.89% | -- |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 461.89% | 461.89% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |